» Articles » PMID: 35062729

Attitudes of Poles Towards the COVID-19 Vaccine Booster Dose: An Online Survey in Poland

Overview
Date 2022 Jan 22
PMID 35062729
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: COVID-19 vaccination has now become the most effective way to combat the pandemic, but there is a gradual decline in the protection that it offers over time. Therefore, the Food and Drug Administration (FDA) and EMA now recommend the use of the so-called booster dose, especially in at-risk groups. The purpose of the study was to assess the attitudes of Poles towards the recommendation to receive a booster dose of the COVID-19 vaccine and to evaluate the main reasons for refusing or delaying the decision.

Material And Methods: The study was based on a proprietary questionnaire distributed via the Internet. There were 1598 respondents, 54 of which did not consent to participate in the survey and/or did not complete the vaccination against SARS-CoV-2. As a result, 1528 surveys were included in the final analysis. The vast majority of the respondents, namely 1275 (83.4%), were female, and 772 (50.5%) were residents of cities with a population of over 250,000.

Results: Out of all respondents, 38 (2.5%) had already received the COVID-19 vaccine booster dose and 1031 (67.4%) would like to receive it as soon as possible. Forty-five (2.9%) respondents reported that they were completely unwilling to take the booster dose. The occurrence of adverse events after primary vaccination were reported by 79.9% of the survey participants. The most common reasons why the respondents refused to be vaccinated are lack of confidence in the effectiveness of the booster dose and the occurrence of adverse events in them or their loved ones. Age, gender, residence, or relationship status were not shown to affect attitudes towards the expansion of the basic vaccination schedule.

Conclusions: One in three respondents plans to delay or refrain from taking the COVID-19 vaccine booster dose. The main reason for refusal to be vaccinated is the belief that the previous vaccination provides sufficient protection.

Citing Articles

Using cluster analysis to explore COVID-19 vaccine booster hesitancy by levels of medical mistrust in fully vaccinated US adults.

Paulus K, Bauerle Bass S, Cabey W, Singley K, Luck C, Hoadley A Ann Med. 2024; 56(1):2401122.

PMID: 39258584 PMC: 11391872. DOI: 10.1080/07853890.2024.2401122.


The continuance intention to vaccinate against COVID-19: An empirical study from Malaysia.

Hwang L, Vaithilingam S, Ng J, Nair M, Ahmed P, Musa K PLoS One. 2024; 19(4):e0301383.

PMID: 38687718 PMC: 11060549. DOI: 10.1371/journal.pone.0301383.


The Prevalence and Determinants of Hesitancy for Regular COVID-19 Vaccination among Primary Healthcare Patients with Asthma or COPD in Greece: A Cross-Sectional Study.

Bouloukaki I, Christodoulakis A, Papageorgakopoulou S, Tsiligianni I Vaccines (Basel). 2024; 12(4).

PMID: 38675796 PMC: 11054093. DOI: 10.3390/vaccines12040414.


Vaccine hesitancy for the COVID-19 vaccine booster dose among nursing home staff fully vaccinated with the primary vaccination course in Belgium.

Digregorio M, Van Ngoc P, Delogne S, Meyers E, Deschepper E, Dardenne N Vaccine X. 2024; 16:100453.

PMID: 38361529 PMC: 10867438. DOI: 10.1016/j.jvacx.2024.100453.


Investigation of the influencing factors with the uptake of the COVID-19 vaccine booster dose among the general population of Ardabil, Iran: A cross-sectional study.

Nejhaddadgar N, Jafarzadeh M, Khazir Z, Yoosefi Lebni J, Rostami M, Janjani P Health Sci Rep. 2023; 6(8):e1494.

PMID: 37621386 PMC: 10444984. DOI: 10.1002/hsr2.1494.


References
1.
Shrotri M, Navaratnam A, Nguyen V, Byrne T, Geismar C, Fragaszy E . Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet. 2021; 398(10298):385-387. PMC: 8285117. DOI: 10.1016/S0140-6736(21)01642-1. View

2.
Abu-Raddad L, Chemaitelly H, Yassine H, Benslimane F, Al Khatib H, Tang P . Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. J Travel Med. 2021; 28(7). PMC: 8194836. DOI: 10.1093/jtm/taab083. View

3.
Payne R, Longet S, Austin J, Skelly D, Dejnirattisai W, Adele S . Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell. 2021; 184(23):5699-5714.e11. PMC: 8519781. DOI: 10.1016/j.cell.2021.10.011. View

4.
Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S . Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021; 385(7):585-594. PMC: 8314739. DOI: 10.1056/NEJMoa2108891. View

5.
Cascini F, Pantovic A, Al-Ajlouni Y, Failla G, Ricciardi W . Attitudes, acceptance and hesitancy among the general population worldwide to receive the COVID-19 vaccines and their contributing factors: A systematic review. EClinicalMedicine. 2021; 40:101113. PMC: 8411034. DOI: 10.1016/j.eclinm.2021.101113. View